Rapamycin Blocks Production of KSHV/HHV8: Insights into the Anti-Tumor Activity of an Immunosuppressant Drug
2011

Rapamycin Blocks Production of KSHV/HHV8: Insights into the Anti-Tumor Activity of an Immunosuppressant Drug

publication 10 minutes Evidence: moderate

Author Information

Author(s): Lisa A. Nichols, Laura A. Adang, Dean H. Kedes

Primary Institution: University of Virginia

Hypothesis

Rapamycin may block the essential transition of KSHV from latency to lytic replication.

Conclusion

Rapamycin inhibits KSHV lytic replication by suppressing the expression of the lytic switch protein RTA, which may explain its clinical success in treating Kaposi's sarcoma.

Supporting Evidence

  • Rapamycin treatment led to a significant reduction in RTA expression in BCBL-1 cells.
  • Treatment with rapamycin blocked the production of progeny virions.
  • Rapamycin inhibited the lytic replication cycle of KSHV without causing cell cycle arrest.

Takeaway

This study shows that a drug called rapamycin can stop a virus that causes cancer from making more copies of itself, which is good for patients with that cancer.

Methodology

The study used latently infected human B cell lines to test the effects of rapamycin on KSHV lytic replication and RTA expression.

Limitations

The study primarily focused on a specific cell line, which may not fully represent all KSHV-infected cells.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1371/journal.pone.0014535

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication